Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitus
- PMID: 9306037
- DOI: 10.1016/s0168-8227(97)00069-7
Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitus
Abstract
We student basal, glucose- and glucagon-induced insulin secretion in non-insulin diabetes mellitus (NIDDM) patients in relation to body mass index (BMI) and fasting serum glucose (FBS) level. A total of 46 NIDDM patients and 22 control subjects with varying degrees of BMI and FBS were given 100 g of oral glucose and 1 mg of intravenous glucagon on separate days. C-peptide response to glucose, but not basal serum C-peptide and C-peptide response to glucagon, was significantly lower in NIDDM than in controls (P < 0.001). FBS was inversely correlated with C-peptide response to glucose in NIDDM patients (r = -0.67, P < 0.001), but not with basal C-peptide level and C-peptide response to glucagon. On the other hand, BMI was positively correlated with basal serum C-peptide level both in NIDDM (r = 0.60, P < 0.001) and in control subjects (r = 0.74, P < 0.001). In 15 poorly controlled NIDDM patients, the tests were repeated after insulin treatment for 10-14 days. C-peptide response to glucose significantly increase, but not to a level in control subjects, after glycemic control. Basal serum C-peptide level and the C-peptide response to glucagon decreased after glycemic control to significantly lower levels than those in the baseline and those in control subjects. These results suggest that beta cell secretory reserve is reduced in moderate to severe NIDDM patients.
Similar articles
-
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.Diabetologia. 1996 Dec;39(12):1546-53. doi: 10.1007/s001250050613. Diabetologia. 1996. PMID: 8960841 Clinical Trial.
-
Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.Eur J Endocrinol. 1996 Oct;135(4):425-32. doi: 10.1530/eje.0.1350425. Eur J Endocrinol. 1996. PMID: 8921824
-
Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus.J Pediatr Endocrinol Metab. 2002 Jan;15(1):59-67. doi: 10.1515/jpem.2002.15.1.59. J Pediatr Endocrinol Metab. 2002. PMID: 11822582 Clinical Trial.
-
Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus--"Flatbush diabetes".J Pediatr Endocrinol Metab. 2002 Apr;15 Suppl 1:493-501. J Pediatr Endocrinol Metab. 2002. PMID: 12017222 Review.
-
Recent advances in diabetes mellitus of interest to dentistry.Spec Care Dentist. 2000 Mar-Apr;20(2):46-52. doi: 10.1111/j.1754-4505.2000.tb01142.x. Spec Care Dentist. 2000. PMID: 11203877 Review.
Cited by
-
Analysis of SNPs of MC4R, GNB3 and FTO gene polymorphism in obese Saudi subjects.Afr Health Sci. 2017 Dec;17(4):1059-1069. doi: 10.4314/ahs.v17i4.14. Afr Health Sci. 2017. PMID: 29937877 Free PMC article.
-
Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes.J Diabetes Investig. 2011 Aug 2;2(4):297-303. doi: 10.1111/j.2040-1124.2010.00096.x. J Diabetes Investig. 2011. PMID: 24843502 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical